SG Americas Securities LLC Makes New $177,000 Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)

SG Americas Securities LLC acquired a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 16,278 shares of the biopharmaceutical company’s stock, valued at approximately $177,000.

Several other hedge funds also recently modified their holdings of the business. ProShare Advisors LLC raised its stake in shares of Sage Therapeutics by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock valued at $257,000 after buying an additional 1,130 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in Sage Therapeutics by 9.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,644 shares of the biopharmaceutical company’s stock valued at $312,000 after acquiring an additional 1,480 shares during the period. Inspire Investing LLC raised its position in Sage Therapeutics by 9.4% in the first quarter. Inspire Investing LLC now owns 19,234 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 1,652 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Sage Therapeutics by 4.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,568 shares of the biopharmaceutical company’s stock worth $723,000 after purchasing an additional 1,693 shares during the period. Finally, Handelsbanken Fonder AB boosted its holdings in Sage Therapeutics by 29.8% during the fourth quarter. Handelsbanken Fonder AB now owns 12,644 shares of the biopharmaceutical company’s stock valued at $274,000 after purchasing an additional 2,900 shares in the last quarter. 99.22% of the stock is owned by institutional investors.

Sage Therapeutics Stock Performance

Shares of SAGE opened at $8.41 on Friday. The business’s fifty day moving average price is $10.31 and its two-hundred day moving average price is $14.35. The firm has a market capitalization of $513.43 million, a price-to-earnings ratio of -1.00 and a beta of 0.90. Sage Therapeutics, Inc. has a 52 week low of $7.70 and a 52 week high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.02). The firm had revenue of $8.65 million during the quarter, compared to the consensus estimate of $8.85 million. Sage Therapeutics had a negative net margin of 458.30% and a negative return on equity of 55.87%. Sage Therapeutics’s revenue was up 249.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.68) EPS. As a group, research analysts forecast that Sage Therapeutics, Inc. will post -6.39 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on SAGE shares. TD Cowen downgraded Sage Therapeutics from a “buy” rating to a “hold” rating and cut their target price for the stock from $16.00 to $10.00 in a research report on Tuesday, July 30th. Robert W. Baird reduced their target price on shares of Sage Therapeutics from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Thursday, July 25th. StockNews.com upgraded shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 27th. The Goldman Sachs Group cut their price target on shares of Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating for the company in a report on Friday, July 26th. Finally, Citigroup started coverage on shares of Sage Therapeutics in a research note on Wednesday, May 29th. They set a “sell” rating and a $8.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $16.06.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.